Granules India Limited (GRANULES) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Granules India Limited stock ₹864, price ₹813, upside +6.2%, quality 52 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Granules India Limited
GRANULES · NSESolid company and rising price, but the stock is already about fairly priced: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range ₹229.88 – ₹909.30 · fair‑value band ₹460.87 – ₹1,080 · the ₹813.20 price screens below the ₹863.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.
Every Wednesday you see whether Granules India is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally.
Show moreShow less
It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions.
In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives.
The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral.
Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Stock analysis
Granules India Limited (GRANULES) currently trades at ₹813.20, while our model-based Fair Value estimate is ₹863.80, so the stock looks roughly fairly valued today (gap 5.8%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹567.94 per share, and 1 of the 26 models we run sit above the ₹813.20 price.
Bear case: the Economic Profit group reads lowest at ₹260.89, and 25 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹460.87 (bear) to ₹1,080 (bull), the price of ₹813.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Granules India Limited reported revenue of ₹53.7B in FY2026 versus ₹37.6B in FY2022, a compound +9.3%/yr. Reported net income was ₹6.0B in FY2026, compounding +9.6%/yr from FY2022.
Key figures
Market cap ₹220B (≈ $2.3B) Mid · P/E ratio 28.5 · P/S ratio 3.74 · EPS (TTM) ₹28.57 · Dividend yield 0.2% · Net margin 12.1% · Return on equity 13.5% · Return on assets (EBIT) 25.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 53% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 6%, GRANULES screens cheaper than that median.
Fair Value models
All 26 models by family
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch GRANULES, get fair value alerts →
Compare Granules India Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs GRANULES |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs GRANULES |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs GRANULES |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs GRANULES |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs GRANULES |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs GRANULES |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs GRANULES |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs GRANULES |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs GRANULES |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs GRANULES |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Granules India Limited (GRANULES) overvalued or undervalued?
What is the fair value of GRANULES?
What is the quality score of GRANULES?
What is the price target for Granules India Limited (GRANULES)?
What is the Granules India Limited stock forecast for 2026?
What is the revenue of Granules India Limited (GRANULES)?
Does Granules India Limited pay a dividend?
How much is the dividend of Granules India Limited (GRANULES) and when is the ex-dividend date?
What growth is priced into Granules India Limited (GRANULES)?
What discount rate (WACC) does the fair value of GRANULES use?
What is a reverse DCF?
How much growth has Granules India Limited (GRANULES) delivered so far?
How fast is the sector of Granules India Limited (GRANULES) growing?
What is the free cash flow yield of Granules India Limited (GRANULES)?
What is the intrinsic value of Granules India Limited (GRANULES)?
Is Granules India Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of GRANULES?
How much is Granules India Limited worth?
What do the bullish and bearish scenarios say about GRANULES?
What is the P/E ratio of GRANULES?
What is the PEG ratio of GRANULES?
How solid is the balance sheet of Granules India Limited (GRANULES)?
How far is GRANULES from its 52-week high?
Which stocks are comparable to Granules India Limited?
Is Granules India Limited stock attractive at the current price?
How is the fair value of GRANULES calculated?
Is it still worth investing in stocks now?
What is the share price of Granules India Limited (GRANULES)?
What should I pay attention to with Granules India Limited right now?
Where does the earnings growth of Granules India Limited (GRANULES) come from?
Key figures of Granules India Limited
How large is the market capitalisation of Granules India Limited (GRANULES)?
What is the P/S ratio of Granules India Limited (GRANULES)?
What are the earnings per share of Granules India Limited (GRANULES)?
What is the dividend yield of Granules India Limited (GRANULES)?
What is the net margin of Granules India Limited (GRANULES)?
What is the return on equity of Granules India Limited (GRANULES)?
What is the EBIT return on assets of Granules India Limited (GRANULES)?
What is the operating margin of Granules India Limited (GRANULES)?
How fast is revenue growing at Granules India Limited (GRANULES)?
How fast are earnings growing at Granules India Limited (GRANULES)?
How much net debt does Granules India Limited (GRANULES) carry?
Watch Granules India Limited in the live analysis
One click puts Granules India Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.